New drug trial aims to sharpen minds in Parkinson's patients

NCT ID NCT05318937

Completed Symptom relief Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested whether an investigational drug called SAGE-718 could improve cognitive performance, specifically thinking speed, in people with Parkinson's disease who have mild thinking problems. 86 participants were randomly assigned to receive either the drug or a placebo for 6 weeks. The main goal was to see if the drug helped people complete a timed symbol-matching test faster, which relates to everyday task performance.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Sage Investigational Site

Sun City, Arizona, 85351, United States
Sage Investigational Site

Little Rock, Arkansas, 72205, United States
Sage Investigational Site

Fresno, California, 93710, United States
Sage Investigational Site

Long Beach, California, 90806, United States
Sage Investigational Site

Los Angeles, California, 90048, United States
Sage Investigational Site

Reseda, California, 91335, United States
Sage Investigational Site

Sacramento, California, 95816, United States
Sage Investigational Site

Englewood, Colorado, 80113, United States
Sage Investigational Site

Vernon, Connecticut, 06066, United States
Sage Investigational Site

Boca Raton, Florida, 33431, United States
Sage Investigational Site

Boca Raton, Florida, 33486, United States
Sage Investigational Site

Hialeah, Florida, 33012, United States
Sage Investigational Site

Miami, Florida, 33032, United States
Sage Investigational Site

Orlando, Florida, 32789, United States
Sage Investigational Site

Port Orange, Florida, 32127, United States
Sage Investigational Site

Tampa, Florida, 33609, United States
Sage Investigational Site

Tampa, Florida, 33613, United States
Sage Investigational Site

Decatur, Georgia, 30030, United States
Sage Investigational Site

Chicago, Illinois, 60611, United States
Sage Investigational Site

Kansas City, Kansas, 66160, United States
Sage Investigational Site

Bloomington, Minnesota, 55425, United States
Sage Investigational Site

Las Vegas, Nevada, 89106, United States
Sage Investigational Site

Albany, New York, 12208, United States
Sage Investigational Site

New York, New York, 10019, United States
Sage Investigational Site

Stony Brook, New York, 11794-8121, United States
Sage Investigational Site

Williamsville, New York, 14221, United States
Sage Investigational Site

Woodmere, New York, 11598, United States
Sage Investigational Site

Raleigh, North Carolina, 27607, United States
Sage Investigational Site

Cincinnati, Ohio, 45221, United States
Sage Investigational Site

Columbus, Ohio, 43221, United States
Sage Investigational Site

Toledo, Ohio, 43614, United States
Sage Investigational Site

Memphis, Tennessee, 38157, United States
Sage Investigational Site

Nashville, Tennessee, 37232, United States
Sage Investigational Site

Houston, Texas, 77030, United States
Sage Investigational Site

San Antonio, Texas, 78229, United States
Sage Investigational Site

Burlington, Vermont, 05401, United States
Sage Investigational Site

Virginia Beach, Virginia, 23502, United States
Sage Investigational Site

Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.

COGNITIVE DYSFUNCTION PARKINSON DISEASE